Cell-specific delivery of ifn-β to T cells using nanoparticles for multiple sclerosis treatment

Overview

This research proposes a targeted drug delivery system for multiple sclerosis (MS) treatment using biodegradable nanoparticles that deliver IFN-β specifically to T cells. By encapsulating IFN-β in polymeric nanoparticles coated with anti-CD3 single-chain variable fragment (scFv) antibodies, the technology aims to maximize the therapeutic benefits of IFN-β while minimizing its side effects. The approach addresses a key limitation of current IFN-β therapy: because the cytokine acts on virtually all cell types, its systemic administration produces both beneficial and adverse effects simultaneously. The proposed solution targets IFN-β exclusively to T cells, where it produces protective effects in MS and its animal model, experimental autoimmune encephalomyelitis (EAE).

Technical specifications

Core technology components:

• Biodegradable polymeric nanoparticles made from pharmacologically approved polymers
• Encapsulated IFN-β (both mouse and human recombinant versions)
• Surface coating with recombinant anti-CD3 scFv antibodies that recognize T cells without activating them
• The nanoparticles are designed to release IFN-β upon reaching target T cells

Key advantages over conventional IFN-β therapy:

• Cell-specific targeting reduces off-target effects on other cell types
• Biodegradable polymer composition supports clinical translation
• The anti-CD3 scFv antibody binds without activating T cells, preventing unintended immune responses
• Potential to drive differentiation of naive T cells into regulatory phenotypes, addressing the autoimmune basis of MS

Validation approach:

• Comparative studies in EAE mouse models (wild-type and IFNAR1 transgenic mice with T-cell-exclusive IFN-I receptor expression)
• In vitro immunoassays using peripheral blood from MS patients and healthy controls
• Assessment of clinical activity, T-cell profiles, and central nervous system neurophysiology
• Testing with monocytes differentiated into dendritic cells presenting myelin antigens to homologous T cells

Technology readiness level

The technology is currently at an early-to-mid stage of development. The research team has established proof-of-concept through previous studies using transgenic mice expressing functional IFN-I receptors exclusively on T cells, demonstrating that T-cell-restricted IFN-β signaling provides superior protection in EAE compared to wild-type mice. Future validation steps include producing recombinant IFN-β and anti-CD3 scFv antibodies, manufacturing and characterizing the nanoparticles, and conducting comprehensive in vivo and in vitro studies comparing NP-IFN-β with conventional IFN-β administration. The use of pharmacologically approved biodegradable polymers positions the technology favorably for eventual clinical translation.